GENMAB A/S Genmab A/S Share Price Deutsche Boerse AG
Equities
GE9
DK0010272202
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 259 EUR | -1.75% |
|
+1.13% | -9.88% |
| 04/06 | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
| 03/06 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
| Sales 2024 * | 19.8B 2.89B 2.65B 241B | Sales 2025 * | 23.62B 3.45B 3.16B 288B | Capitalization | 125B 18.21B 16.7B 1,520B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 684M 627M 57.04B | Net income 2025 * | 6.61B 966M 885M 80.59B | EV / Sales 2024 * | 4.99 x |
| Net cash position 2024 * | 25.92B 3.78B 3.47B 316B | Net cash position 2025 * | 32.36B 4.73B 4.33B 394B | EV / Sales 2025 * | 3.91 x |
| P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.5
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -1.75% | ||
| 1 week | +1.13% | ||
| Current month | +0.27% | ||
| 1 month | -4.60% | ||
| 3 months | -1.78% | ||
| 6 months | -10.72% | ||
| Current year | -9.88% |
1 week
259.00
264.70
1 month
256.10277.90
Current year
246.70296.50
1 year
246.70372.00
3 years
246.70445.10
5 years
145.00445.10
10 years
27.55445.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
| Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 01/16/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | 263.6 | +1.35% | 36 |
| 05/24/05 | 260.1 | -0.88% | 30 |
| 04/24/04 | 262.4 | 0.00% | 30 |
| 03/24/03 | 262.4 | +1.59% | 125 |
| 31/24/31 | 258.3 | +0.86% | 21 |
Delayed Quote Deutsche Boerse AG, June 07, 2024 at 01:20 am IST
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
10/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,940
DKK
Average target price
2,464
DKK
Spread / Average Target
+26.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.33% | 125B | |
| +13.95% | 108B | |
| -3.53% | 24.57B | |
| +2.71% | 22.82B | |
| -41.48% | 16.54B | |
| -12.62% | 16.5B | |
| +0.99% | 13.39B | |
| +21.79% | 11.1B | |
| +84.48% | 9.22B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
